Skip to main content

Market Overview

Biogen, InnoCare Collaborate On Multiple Sclerosis Candidate

Share:
Biogen, InnoCare Collaborate On Multiple Sclerosis Candidate
  • Biogen Inc (NASDAQ: BIIBis paying $125 million upfront to work on InnoCare Pharma Limited's orelabrutinib, a small oral molecule Bruton's tyrosine kinase inhibitor (BTKi) for multiple sclerosis.
  • InnoCare is eligible to receive up to $812.5 million in potential milestone payments, as well as a percentage of sales, should it gain approval.
  • With the ability to cross the blood-brain barrier, orelabrutinib could stop B cell and myeloid cell effector functions in the central nervous system.
  • The candidate is currently being investigated in a global Phase 2 study in relapsing-remitting multiple sclerosis patients.
  • Price Action: BIIB shares closed at $349.04 on Monday.
 

Related Articles (BIIB)

View Comments and Join the Discussion!

Posted-In: Briefs multiple sclerosisBiotech News Health Care Contracts General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com